Loading
A phase 3 trial of Nemtabrutinib, Venetoclax and Rituximab in chronic lymphocytic leukaemia and non-Hodgkin lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). is a phase 3 interventional study registered as NCT05947851 by Merck Sharp & Dohme LLC, with 735 participants planned, started 2023-08-08 and due to reach its primary completion in 2032-06-01. Interventions recorded: Nemtabrutinib, Venetoclax and Rituximab.
Shares BCL-2 inhibitors, Relapsed or refractory chronic lymphocytic leukaemia, Venetoclax, Rituximab and the tag pipeline.
Shares BCL-2 inhibitors, Relapsed or refractory chronic lymphocytic leukaemia, Venetoclax, Rituximab and the tag pipeline.
Shares BCL-2 inhibitors, Relapsed or refractory chronic lymphocytic leukaemia, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia, Monoclonal antibodies and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Nemtabrutinib, Rituximab, Chronic lymphocytic leukaemia, Merck & Co. (MSD) and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia, Monoclonal antibodies and the tag pipeline.